Pathogenesis of calcineurin inhibitor-induced hypertension
about
Caerulomycin A suppresses immunity by inhibiting T cell activityExposure to nerve growth factor worsens nephrotoxic effect induced by Cyclosporine A in HK-2 cellsPosttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trialAmerican Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.Drug-induced blood pressure increase - recommendations for assessment in clinical and non-clinical studies.Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction.NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.A new twist on an old idea part 2: cyclosporine preserves normal mitochondrial but not cardiomyocyte function in mini-swine with compensated heart failurePreventing Allograft Rejection by Targeting Immune Metabolism.Calcineurin and Sorting-Related Receptor with A-Type Repeats Interact to Regulate the Renal Na⁺-K⁺-2Cl⁻ CotransporterComparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta.Lovastatin attenuates effects of cyclosporine A on tight junctions and apoptosis in cultured cortical collecting duct principal cells.A new twist on an old idea: a two-dimensional speckle tracking assessment of cyclosporine as a therapeutic alternative for heart failure with preserved ejection fraction.Hypertension after kidney transplantation: a pathophysiologic approach.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Identifiable hypertension: a new spectrum.Calcineurin inhibitors and hypertension: a role for pharmacogenetics?Central modulation of cyclosporine-induced hypertension.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.Factors associated with cardiovascular target organ damage in children after renal transplantation.Pregnancy outcomes in liver transplant recipients: A 15-year single-center experience.Liver Transplantation: the Role of Metabolic Syndrome.Drug-Induced Hypertension: Focus on Mechanisms and Management.Unique Considerations When Managing Hypertension in the Transplant Patient.Cyclosporine A and lovastatin: the good and the bad, but who will be the winner?Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.Comprehensive review of cardiovascular toxicity of drugs and related agents.Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms.Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment.Vasomotor dysfunction in the mesenteric artery after organ culture with cyclosporin A.An Unusual Manifestation of Calcineurin Inhibitor-Induced Pain Syndrome in Kidney Transplantation: A Case Report and Literature Review.Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system.American Heart Association High Blood Pressure Protocol 2017: A Literature ReviewRole of the alternative splice variant of NCC in blood pressure control
P2860
Q27348735-2772241C-6953-42FE-BB81-7D3A46B90E9BQ28534915-B35B6DC0-4D5A-4CE6-B709-B5A381F2CD25Q28647771-854AB050-10BA-4F48-8BBF-B3079BBD54ADQ30277654-448A1DBC-4F4E-4C2B-AD94-2484037BE3ABQ30395099-D008FAC3-4ADB-47A3-9E7A-BBB39DF6ABFCQ30405394-CD47EB01-DAE9-4404-A900-BC1FA480B7A7Q33590418-F26C5681-B867-49EE-8B85-62574496654AQ34399914-BEBFB2E0-0DB8-4BE3-A918-F29EDBEEA9EAQ36225691-5FD781E0-A340-496B-A52A-FDE62FDB590AQ36417867-63D84486-A36F-48E4-89D2-918C24174979Q36988437-C9A412E9-0007-43CA-A656-23023C8A8E57Q37093668-FF405547-F4CE-4D7C-B454-93C325736500Q37675569-25E1CF54-9C52-4C06-875B-B31C97AD1329Q38128162-1D69758B-907A-44E4-B704-607A7AD292D9Q38136748-6FBF4AC4-340C-4336-81E8-B1988E3C3419Q38148619-311A2651-5949-4B75-B86C-E1433AC6134FQ38241677-CDE7E5E0-D220-4332-9F29-E2F7CA19A9CEQ38272109-D4A00166-B621-4B5E-AD85-F0178A0ED9E2Q38411930-F8E41DCF-C0D1-4216-8518-1CD40013CF19Q38626501-92312C55-FC2D-4598-8CF0-8975002C4DF9Q38936343-DEA3A500-D452-4DF0-81BC-FA676B7641E5Q39255762-B6ACAB8D-E08A-419D-8457-73AB16D01C38Q39268826-FB17EDAF-1B40-4D20-A953-0A63BC44883CQ40488379-138919BA-7B0D-4FAD-BC31-AE0897088B02Q44294762-608239D8-8F9C-4827-A658-95DDB9008AD8Q47318170-69A5B77D-EC54-4AE3-ACE7-DD9F6DB609D8Q47556269-019A7D4A-2B27-4C50-806E-6CB4ADA28538Q48008398-1BFFA91D-6EE5-416F-A330-E78606304FFDQ48224764-0B7179D3-24FC-4D4F-BEE3-02E3207B2D8FQ50870949-530F541C-6FCD-420D-8A6B-302D236A9AFFQ52589116-E08CE864-5753-4C0D-8248-FE902A121464Q53860769-7C78058F-F930-4BCD-B4E3-B4E037AB03FBQ58563980-B0A3A4E3-7A8F-4D22-AC56-5990FD498A58Q58795991-8E81D3E9-C9C7-439D-9C94-9E218926CED6
P2860
Pathogenesis of calcineurin inhibitor-induced hypertension
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pathogenesis of calcineurin inhibitor-induced hypertension
@ast
Pathogenesis of calcineurin inhibitor-induced hypertension
@en
type
label
Pathogenesis of calcineurin inhibitor-induced hypertension
@ast
Pathogenesis of calcineurin inhibitor-induced hypertension
@en
prefLabel
Pathogenesis of calcineurin inhibitor-induced hypertension
@ast
Pathogenesis of calcineurin inhibitor-induced hypertension
@en
P2093
P2860
P356
P1476
Pathogenesis of calcineurin inhibitor-induced hypertension
@en
P2093
David H Ellison
Ewout J Hoorn
James A McCormick
Robert J Unwin
Robert Zietse
Stephen B Walsh
P2860
P304
P356
10.5301/JN.5000174
P577
2012-05-01T00:00:00Z